Con: Can biomarkers be gold standards in Alzheimer's disease?

TY - JOUR

T1 - Con

T2 - Can biomarkers be gold standards in Alzheimer's disease?

AU - Rockwood, Kenneth

N1 - Funding Information: This paper endorses the systematic assessment of patient and caregiver preferences in dementia, which is facilitated by software commercialized by DementiaGuide Inc., of which the author is president, chief scientific offi cer and majority shareholder. KR receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research. Support for the research summarized in the present article came from the Canadian Institutes for Health Research, Janssen Ortho Canada, the Alzheimer Society of Canada, the Mathematics of Information Technology and Computer Science program of the Canadian Research Network, and the Fountain Innovation Fund of the Queen Elizabeth II Health Sciences Foundation. DementiaGuide Inc. has received funding from the Atlantic Canada Opportunities Agency, and the National Research Council of Canada, through the Industrial Research Assistance Program.

PY - 2010

Y1 - 2010

UR - http://www.scopus.com/inward/record.url?scp=77954159694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954159694&partnerID=8YFLogxK

U2 - 10.1186/alzrt40

DO - 10.1186/alzrt40

M3 - Short survey

AN - SCOPUS:77954159694

SN - 1758-9193

VL - 2

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

IS - 3

M1 - 16

ER -